SYRESpyre Therapeutics, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$16.9M, 90 days to Oct 8, 2026), selling is often routine.
Large price swings, high volatility. Worst drawdown -99% · now 21% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can SYRE take a bad year?
The deepest fall in SYRE's price history on file is −99%; it is 21% below its high today.
Altman Z-score · distress below 1.8 · safe above 3 · safe zone, the balance sheet is not what threatens this one
- Annualised volatility
- 69%
Annualised volatility · three times the market's own swing
- Worst drawdown on file
- −99%
Worst drawdown on file · −21% today
Details›
- Cash and short-term investments
- $1.15B
- Operating profit, trailing twelve months
- −$201M
- Annualised volatilitytwo years of daily moves
- 69%
- Worst drawdown on file
- −99%
- Below its 52-week high
- 21%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.